Skip to main content

Advertisement

SpringerLink
Log in

Is heart failure different on the two continents (North America and Europe)?

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Heart failure is increasing in both North America and Europe. Although many similarities in the disease are apparent between the two continents, differences do exist. Heart failure with preserved systolic function appears to be increasingly important on both continents, and is associated more frequently with hypertension, aging, and female sex. Treatment guidelines from the two continents show more similarities than differences, though different treatment patterns emerge. Because more patients with heart failure will be older in the future, clinical trials that include greater numbers of these patients are needed to demonstrate that therapies are as effective and safe in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Klainer LM, Gibson TC, White KL: The epidemiology of cardiac failure. H Chronic Dis 1965, 18:797–781.

    Article  CAS  Google Scholar 

  2. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2002.

    Google Scholar 

  3. Klein L, O'Connor M, Gattis WA, et al.: Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003, 91(Suppl):18F-40F.

    Article  PubMed  CAS  Google Scholar 

  4. Maisel WH, Stevenson LW: Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91(Suppl):2D-8D.

    Article  PubMed  Google Scholar 

  5. Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397–1402. Examines Framingham Heart Study patients with respect to the changing incidence and survival of patients with HF from the 1950s through the 1990s. Provides a nice figure illustrating the decreasing mortality of HF patients over the time period studied, and examines sex differences.

    Article  PubMed  Google Scholar 

  6. Redfield MM: Heart failure—an epidemic of uncertain proportions. N Engl J Med 2002, 347:1442–1444. Points out potential oversights in the summary of the Framingham Heart Study data presented by Levy et al. [5].

    Article  PubMed  Google Scholar 

  7. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194–202. Determines prevalence of HF by survey of residents of Minnesota over the age of 45 years. Uses Framingham criteria and echocardiography to diagnose HF, evaluates the prevalence of systolic and diastolic dysfunction, and finds diastolic dysfunction to be a predictor of mortality.

    Article  PubMed  Google Scholar 

  8. McCullough PA, Philibin EF, Spertus JA, et al.: Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol 2002, 39:60–69.

    Article  PubMed  Google Scholar 

  9. Ho KK, Anderson KM, Kannel WB, et al.: Survival after the onset of congestive heart failure in Framingham Heart Study subjectsv. Circulation 1993, 88:107–115.

    PubMed  CAS  Google Scholar 

  10. Krum H, Gilbert RE: Demographics and concomitant disorders in heart failure. Lancet 2003, 362:147–158. Good literature-based review of demographics of HF from epidemiologic studies over the past 10 years. Provides a detailed reference table of studies, which lists patient characteristics with respect to age, sex, and comorbidities.

    Article  PubMed  Google Scholar 

  11. Jong P, Vowinckel E, Liu PP, et al.: Prognosis and determinant of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002, 162: 689–1694. Retrospective study of 38,702 patients with HF from the Canadian Institute for Health Information database. Provides data on 30-day and 1-year mortality with respect to age and comorbidities for this Canadian population.

    Article  Google Scholar 

  12. Scott RL: Is heart failure in African Americans a distinct entity? CHF 2003, 9:193–196.

    PubMed  CAS  Google Scholar 

  13. Heiat A, Gross CP, Krumholz HM: Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002, 162:1682–1688.

    Article  PubMed  Google Scholar 

  14. Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001, 22:1527–1560.

    Article  PubMed  CAS  Google Scholar 

  15. Cleland JG, Cohen-Solal A, Aguilar JC, et al.: Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): an international survey. Lancet 2002, 360:1631–1639. A survey of primary care physicians who treat patients with HF in 15 countries of Europe. Provides good epidemiologic data and information on treatment practices, organized by country

    Article  PubMed  CAS  Google Scholar 

  16. Parameshwar J, Shackell MM, Richardson A, et al.: Prevalence of heart failure in three general practices in northwest London. Br J Gen Pract 1992, 42:287–289.

    PubMed  CAS  Google Scholar 

  17. Wheeldon NM, MacDonald TM, Flucker CJ, et al.: Echocardiography in chronic heart failure. Q J Med 1993, 86:17–23.

    PubMed  CAS  Google Scholar 

  18. Opasich C, De Giuli F, Majani G, et al.: Current perspectives. Heart failure woman: does she make any difference? Ital Heart J 2003, 4:4–16. Summarizes epidemiology, treatment, and mortality data of women represented in the major HF clinical trials. Presents sex-specific data for specific countries in Europe as well as the United States.

    PubMed  Google Scholar 

  19. Remes J, Reunanen A, Aromaa AA, Pyorala K: Incidence of heart failure in Eastern Finland: a population based surveillance study. Eur Heart J 1992:13:588–593.

    PubMed  CAS  Google Scholar 

  20. Stewart S, MacIntyre K, Capewell S, McMurray JJ: Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003, 89:49–53.

    Article  PubMed  CAS  Google Scholar 

  21. Westert GP, Lagoe RJ, Keskimaki I, et al.: An international study of hospital readmission and related utilization in Europe and the USA. Health Policy 2002, 61:269–278.

    Article  PubMed  Google Scholar 

  22. Fonarow GC, Horwich TB: Prevention of heart failure: effective strategies to combat the growing epidemicv. Rev Cardiovasc Med 2003, 4:8–17.

    PubMed  Google Scholar 

  23. Lewis EF, Moye LA, Rouleau JL, et al.: Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003, 42:1446–1453. Good study for evaluating heart failure predictors in the post-MI setting.

    Article  PubMed  Google Scholar 

  24. Hellerman JP, Goraya TY, Jacobsen SJ, et al.: Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol 2003, 157:1101–1107.

    Article  Google Scholar 

  25. Bell DS: Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003, 26:2433–2441.

    Article  PubMed  Google Scholar 

  26. Amato L, Paolisso G, Cacciatore F, et al.: Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly: the Osservatorio Geriatico Regione Campania group. Diabetes Metab 1997, 23:213–218.

    PubMed  CAS  Google Scholar 

  27. Kannel SB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035–2038.

    Article  PubMed  CAS  Google Scholar 

  28. Nichols GA, Hillier TA, Erby JR, Brown JB: Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001, 24:1614–1619.

    Article  PubMed  CAS  Google Scholar 

  29. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003, 362:777–781.

    Article  PubMed  CAS  Google Scholar 

  30. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-added trial. Lancet 2003, 362:767–771.

    Article  PubMed  CAS  Google Scholar 

  31. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003, 362:759–766.

    Article  PubMed  CAS  Google Scholar 

  32. Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors, the CHARM-alternative trial. Lancet 2003, 262:772–776.

    Article  CAS  Google Scholar 

  33. Poole-Wilson PA, Swedberg K, Cleland JG, et al.: comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet 2003, 362:7–13.

    Article  PubMed  CAS  Google Scholar 

  34. McMurray J, Ostergren J, Pfeffer M, et al.: Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003, 5:261–270.

    Article  PubMed  CAS  Google Scholar 

  35. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left biventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302.

    Article  Google Scholar 

  36. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429–1435.

    Article  Google Scholar 

  37. Stewart S, McIntyre K, Capewell S, McMurray JJ: Heart failure in a cold climate. Seasonal variation in heart failure-related morbidity and mortality. J Am Coll Cardiol 2002, 39:760–766.

    Article  PubMed  Google Scholar 

  38. Kulig M, Erika S, Norbert WS: Comparing methodological quality and consistency of international guidelines for the management of patients with chronic heart failure. Eur J Heart Fail 2003, 5:327–335.

    Article  PubMed  Google Scholar 

  39. Burkhoff D, Maurer MS, Packer M: Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation 2003, 107:656–658.

    Article  PubMed  Google Scholar 

  40. Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714–720.

    Article  PubMed  Google Scholar 

  41. Angeja BG, Grossman W: Evaluation and management of diastolic heart failure. Circulation 2003, 107:659–663.

    Article  PubMed  Google Scholar 

  42. Bradley TD, Floras JS: Sleep apnea and heart failure: part I: obstructive sleep apnea. Circulation 2003, 107:1671–1678.

    Article  PubMed  Google Scholar 

  43. Shahar E, Whitney CW, Redline S, et al.: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the sleep heart health study. Am J Resp Crit Care Med 2001, 163:19–25.

    PubMed  CAS  Google Scholar 

  44. Bradley TD, Logan AG, Floras JS, and the CANPAP Investigators: Rationale and design of the Canadian Continuous Positive Airway Pressure Trial for Congestive Heart Failure patients with Central Sleep Apnea--CANPAP. Can J Cardiol 2001 17:677–684.

    PubMed  CAS  Google Scholar 

  45. Bradley TD, Flora JS: Sleep apnea and heart failure: part II: central sleep apnea. Circulation 2003, 107:1822–1826.

    Article  PubMed  Google Scholar 

  46. McMurray J, Pfeffer MA: New therapeutic options in congestive heart failure: part I. Circulation 2002, 105:2099–2106.

    Article  PubMed  Google Scholar 

  47. Mehra M, Uber PA, Francis GS: Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol 2003, 41:1606–1610.

    Article  PubMed  Google Scholar 

  48. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  49. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, bdin patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.

    Article  PubMed  CAS  Google Scholar 

  50. Komajda M, Follath F, Swedberg K, et al.:and the Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The Euroheart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Eur Heart J 2003, 24:464–475.

    Article  PubMed  CAS  Google Scholar 

  51. Saxon, LA, Ellenbogen KA: Resynchronization therapy for the treatment of heart failure. Circulation 2003, 108:1044–1048.

    Article  PubMed  Google Scholar 

  52. Francis GS, Tang WH: Pathophysiology of congestive heart failure. Rev Cardiovasc Med2003, 4(Suppl 2):S14-S20.

    PubMed  Google Scholar 

  53. Baliga RR, Narula J: Pharmacogenomics of congestive heart failure. Med Clin North Am 2003, 87:569–578.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland VA Medical Center, Case Western Reserve University, 10701 East Boulevard, 44106, Cleveland, OH, USA

    Mark E. Dunlap MD

Authors
  1. Rachel Hughes-Doichev MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Dunlap MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hughes-Doichev, R., Dunlap, M.E. Is heart failure different on the two continents (North America and Europe)?. Curr Cardiol Rep 6, 182–188 (2004). https://doi.org/10.1007/s11886-004-0021-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-004-0021-z

Keywords

Search

Navigation